alexa Targeting Brutons Tyrosine Kinase in Chronic Lymphocyti
ISSN: 2329-6917

Journal of Leukemia
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals

Federica Frezzato1,2*, Valentina Trimarco1,2, Andrea Visentin1,2, Veronica Martini1,2, Filippo Severin1,2, Monica Facco1,2, Gianpietro Semenzato1,2 and Livio Trentin1,2

1Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Italy

2Venetian Institute of Molecular Medicine (VIMM), Padua, Italy

*Corresponding Author:
Federica Frezzato
Department of Medicine, Hematology and Clinical Immunology Unit
University of Padua, Italy
Tel: 0039-049-821-2298
Fax: 0039-049-821-1970
E-mail: [email protected]

Received date: February 16, 2016; Accepted date: March 18, 2016; Published date: March 21, 2016

Citation: Frezzato F, Trimarco V, Visentin A, Martini V, Severin F, et al. (2016) Targeting Bruton’s Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals. J Leuk 4:207. doi:10.4172/2329-6917.1000207

Copyright: © 2016 Frezzato F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments. The main goal of the researchers in CLL is the identification of specific targets in order to develop new therapeutic strategies to cure the disease. The Bcell receptor-signalling pathway is necessary for survival of malignant B cells and its related molecules recently become new targets for therapy. Moreover, leukemic microenvironment delivers survival signals to neoplastic cells also overcoming the apoptotic effect induced by traditional drugs. In this context, the investigation of Bruton’s tyrosine kinase (Btk) is useful in: i) dissecting CLL pathogenesis; ii) finding new therapeutic approaches striking simultaneously intrinsic as well as extrinsic pro-survival signals in CLL. This paper will review these main topics.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version